News for CRTX Stock

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections Cortexyme Appoints June Bray to its Board of Directors Cortexyme Appoints Dr. Philip Low to Its Board of Directors Cortexyme Successfully Completes Acquisition of Novosteo Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases Cortexyme Announces Agreement to Acquire Novosteo Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors Cortexyme to Present New GAIN Trial Data at AD/PD 2022 Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588 Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones Cortexyme Announces Change in Executive Leadership Team Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021 Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021 Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit Cortexyme Provides Business Update and Reports Second Quarter 2021 Results Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021 Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection Cortexyme to Present New Data at AAIC 2021 Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 Cortexyme to Host Symposium at AAIC 2021 Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Cortexyme to Present at Investor Conferences in June 2021 Cortexyme Provides Business Update and Reports First Quarter 2021 Results Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences